Could endothelial TGFβ signaling be a promising new target for liver disease?

Expert Rev Gastroenterol Hepatol. 2018 Jul;12(7):637-639. doi: 10.1080/17474124.2018.1477587. Epub 2018 May 30.

Authors

David H Adams¹, Emma L Shepherd¹, Patricia F Lalor¹

Affiliation

¹ a National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Unit, Institute of Immunology and Immunotherapy , University of Birmingham , Birmingham , UK.

PMID: 29799279
DOI: 10.1080/17474124.2018.1477587

No abstract available

Keywords: Endothelium; TGFβ; chronic liver disease; fibrosis; therapy.

Publication types

Editorial

MeSH terms

Animals
Endothelial Cells / drug effects
Endothelial Cells / metabolism*
Endothelial Cells / pathology
Epithelial-Mesenchymal Transition* / drug effects
Humans
Liver / drug effects
Liver / metabolism*
Liver / pathology
Liver Cirrhosis / diagnosis
Liver Cirrhosis / drug therapy
Liver Cirrhosis / metabolism*
Molecular Targeted Therapy
Phenotype
Receptors, Transforming Growth Factor beta / antagonists & inhibitors
Receptors, Transforming Growth Factor beta / metabolism*
Signal Transduction* / drug effects
Transforming Growth Factor beta / antagonists & inhibitors
Transforming Growth Factor beta / metabolism*

Substances

Receptors, Transforming Growth Factor beta
Transforming Growth Factor beta

Grants and funding